An Open-label, Randomized, Single-dose, 4-way Crossover Study to Assess the Relative Bioavailability of Axelopran and Oxycodone Administered as a Fixed-Dose Combination and as Individual Components to Healthy Subjects with a Naltrexone Block Under Fasting Conditions

Trial Profile

An Open-label, Randomized, Single-dose, 4-way Crossover Study to Assess the Relative Bioavailability of Axelopran and Oxycodone Administered as a Fixed-Dose Combination and as Individual Components to Healthy Subjects with a Naltrexone Block Under Fasting Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Axelopran (Primary) ; Axelopran/oxycodone (Primary) ; Oxycodone (Primary) ; Naltrexone
  • Indications Constipation
  • Focus Pharmacokinetics
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 10 Sep 2015 According to a Theravance Biopharma media release, data from this study were presented in a poster presentation at PAINWeek 2015.
    • 10 Sep 2015 Results published in a Theravance Biopharma media release.
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top